Document is current
Any future updates will be listed below
-
Authors
Morgan, Jaida E.
Jaferi, Nishah
Shonibare, Zainab
Huang, Gloria S. https://orcid.org/0000-0002-0001-888X
-
Funding
Funding for this research was provided by:
Congressionally Directed Medical Research Programs (W81XWH-16-1-0196)
National Cancer Institute (P30CA016359)
- License Information
-
More Information
Article History
Received: 5 January 2024
Accepted: 29 April 2024
First Online: 13 May 2024
Declarations
:
: Not Applicable for this Article Type (Review).
: Not Applicable for this Article Type (Review).
: Not Applicable for this Article Type (Review).
: G.S.H. is the Inventor on U.S. Patent 17102992 for Targeting of ARID1A-Deficient Cancers. G.S.H. has received consulting fees from Glaxo Smith Kline and AstraZeneca, outside of the scope of this work.
: The other authors (J. M., N. J., Z.S.) have no relevant financial or non-financial interests to disclose.
